CancERVacc Targeting Cancer with ERV Vaccines
- Coordinator
- Inprother Aps, Denmark
- Runs
- 1 July 2022 to 31 October 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €12.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190120397
What the project is doing
In the project's own words, from its summary on CORDIS.
InProTher (IPT) is developing a unique immunotherapy BreakImmune that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines.
The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types. Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Inprother Aps | Kbenhavn N | Denmark | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI